Clinical Trial Update: Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating switching virologically suppressed HIV-1 patients with archived M184V/M184I mutations to an elvitegravir/cobicistat/emtricitabine/ten…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2019-11-04